Fungal Esophagitis: Molecular Insights Into Pathogenesis and Emerging Antifungal Strategies. (PubMed, Front Biosci (Landmark Ed)) - Sep 4, 2026 - "While fluconazole remains the first-line agent for most cases, the increasing prevalence of non-albicans Candida species and drug resistance underscore the importance of alternative medications with different molecular targets. Agents such as the recently approved rezafungin as well as compounds such as ibrexafungerp and fosmanogepix, represent promising options for the treatment of refractory disease. This review synthesizes current advances in the molecular pathogenesis of fungal esophagitis, with particular emphasis on host-fungal interactions, antifungal resistance mechanisms, and novel treatment strategies. A deeper understanding of these processes is essential to improve management and to guide the development of innovative immunomodulatory and antifungal therapies."
IO biomarker • Journal • Review • Eosinophilic Esophagitis • Gastrointestinal Disorder • Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • Solid Organ Transplantation • Transplantation • IL17A
|
|
Christos Triantos; Ioanna Aggeletopoulou; Konstantinos Papantoniou; Ploutarchos Pastras
|